Abstract: Absence of effective therapeutic methods for avascular necrosis of femoral head (ANFH) is still perplexing the world's medical community. Bone marrow mesenchymal stem cells (BMSCs) adoptive cell therapy combined with core decompression is a promising modality, which is highly dependent on the cellular activities of BMSCs. Hepatocyte growth factor (HGF) is a survival factor for BMSCs, yet the underlying mechanism is not fully elucidated. In this study, the effects of multiplicity of infections (MOIs) of recombinant adenovirus carrying HGF gene (rAd-HGF) on human BMSC proliferation and osteogenic differentiation were systemically examined. Infection of rAd-HGF produced secretory HGF and promoted hBMSC proliferation in a MOI-dependent manner, while the osteogenesis was also strengthened as indicated by enhanced calcium nodule formation with the strongest effects achieved at MOI = 250. Blocking the activities of c-MET or its downstream signaling pathways, WNT, ERK1/2, and PI3K/AKT led to differential consequents. Specifically, blockage of the WNT pathway significantly promoted osteogenic differentiation, which also showed additive effects when combined application with rAd-HGF. Our data demonstrated the pro-osteogenic effects of optimized MOIs of rAd-HGF, while inhibition of WNT pathway or activation of PI3K/AKT pathway may act as candidate adjuvant modalities for promoting osteogenic differentiation in rAd-HGF-modified hBMSC treatment on ANFH.
Introduction
Avascular necrosis of the femoral head (ANFH) is a common and frequently-occurring disease, mainly occurring in adults aged 20-50 years old. The disability rate of ANFH is extremely high, seriously affecting the life quality and working capacity of patients, resulting in a huge burden for society and families. Around 30 million people worldwide are suffering from the disease, and the incidence is still growing.
Currently, there is no effective cure for ANFH [1] , and this has become the challenge to be jointly tackled by the world's medical community. Interventional therapies, medullary core decompression, vascularized bone graft surgery, osteotomy, etc., have been used at the early stages (Ficat stage I and II), yet nearly all of them could not stop the development of disease. When advanced to stage III and the WNT signaling pathway, translocating into the nucleus following c-MET activation and involving in the transcriptional regulation of a large number of genes [17] . Classic WNT signaling pathway promotes osteoblastic differentiation of BMSCs early in osteogenesis by relying on or not relying on the osteogenic differentiation of key transcription factor runt-related transcription factor 2 (Runx2) [18] . Clearly, each of signal pathways coordinated the control on cell activity. Therefore, fully aware of the effects of different HGF levels on the c-MET downstream signaling pathways related to osteogenic differentiation and proliferation will provide theoretical support for a more rational use of HGF to promote BMSC effect on bone tissue repair in osteogenic environments.
In this study, we generated HGF-gene modified hBMSCs using rAd-HGF and tested the effects of low MOI (MOI = 10 or 50) and high MOIs (MOI = 250 or 1250) on the expression of HGF which was thought to be critical regulator in ANFH therapy. Our results indicated that higher MOIs of rAd-HGF (MOI = 250 or 1250) not only significantly promote HGF expression, but also play stronger roles in enhancing hBMSC proliferation and osteogenic differentiation than rAd-Ctrl and low MOIs of rAd-HGF (MOI = 10 or 50). Inhibitor-specific blockage of signaling pathways showed that the WNT signaling pathway plays anti-osteogenic roles while the PI3K/AKT pathway is pro-osteogenic for hBMSCs. Our findings not only indicated the optimized MOI of rAd-HGF for preparing HGF-gene modified hBMSCs, but also suggested that the WNT pathway is a promising inhibitory target for treatment of ANFH using rAd-HGF-modified hBMSCs.
Results

The Effects of rAd-HGF MOI on the Expression of HGF in hBMSCs
Human BMSCs naturally express HGF in a relatively low level [19] . To explore whether the expression levels of HGF in hBMSCs from rAd-HGF infection are dependent on the MOI, the concentrations of secretory HGF protein in the growth medium of hBMSCs infected by serial MOIs of rAd-HGF were detected by ELISA every two days for about two weeks. As predicted, control adenovirus (rAd-Ctrl)-infected hBMSCs maintained the secretion of HGF, while low MOI (MOI = 10) of rAd-HGF brought out the similar HGF concentrations during a 13-day observation period ( Figure 1A ). In contrast, significant increase in HGF secretion compared with the rAd-Ctrl infection group could be observed in higher MOI (MOI = 50) of rAd-HGF infection (p < 0.05; Figure 1B ). The peak concentration of HGF in the supernatants was detected at MOI = 250 ( Figure 1C) , and the significant upregulation of secretory HGF concentrations was maintained with ascending MOIs to the highest MOI detected in this study (MOI = 1250; Figure 1D ). The above results indicated that overexpression of HGF could be achieved by infection of hBMSCs with higher MOIs (MOI ≥ 50) of rAd-HGF.
Evaluating the Pro-Proliferative Effects of Serial rAd-HGF MOIs on hBMSCs
To investigate the influence of serial MOIs of rAd-HGF infection on hBMSC proliferation, the cell viability analysis was performed following rAd-HGF infection. Results of the WST-8 assays indicated that in growth medium, relative lower doses of HGF obtained by rAd-HGF infection at MOI = 10 or 50 could not significantly promote cell growth compared with the effects of rAd-Ctrl. At MOI = 10, there was no difference in proliferation between cells infected with rAd-HGF and those infected with rAd-Ctrl (Figure 2A ). Although there was some elevation in cell amounts resulting from infection with rAd-HGF compared with rAd-Ctrl at MOI = 50, such a significant difference disappeared beginning at five days post infection ( Figure 2B ). However, the enhanced cell proliferation became more significant starting from the second day after higher MOIs (MOI = 250 or 1250) of rAd-HGF infection, which is probably owing to the higher HGF expression induced by rAd-HGF infection with the higher MOIs. Such pro-proliferative effects became more remarkable at the later timepoints of the observation period ( Figure 2C,D) . Consistent with the secretion of HGF, the highest level of cell proliferation was observed in cells infected with rAd-HGF at MOI = 250 ( Figure 2C ). 1A). In contrast, significant increase in HGF secretion compared with the rAd-Ctrl infection group could be observed in higher MOI (MOI = 50) of rAd-HGF infection (p < 0.05; Figure 1B) . The peak concentration of HGF in the supernatants was detected at MOI = 250 ( Figure 1C) , and the significant upregulation of secretory HGF concentrations was maintained with ascending MOIs to the highest MOI detected in this study (MOI = 1250; Figure 1D ). The above results indicated that overexpression of HGF could be achieved by infection of hBMSCs with higher MOIs (MOI ≥ 50) of rAd-HGF. 
To investigate the influence of serial MOIs of rAd-HGF infection on hBMSC proliferation, the cell viability analysis was performed following rAd-HGF infection. Results of the WST-8 assays indicated that in growth medium, relative lower doses of HGF obtained by rAd-HGF infection at MOI = 10 or 50 could not significantly promote cell growth compared with the effects of rAd-Ctrl. At MOI = 10, there was no difference in proliferation between cells infected with rAd-HGF and those infected with rAd-Ctrl (Figure 2A ). Although there was some elevation in cell amounts resulting from infection with rAd-HGF compared with rAd-Ctrl at MOI = 50, such a significant difference disappeared beginning at five days post infection ( Figure 2B ). However, the enhanced cell proliferation became more significant starting from the second day after higher MOIs (MOI = 250 or 1250) of rAd-HGF infection, which is probably owing to the higher HGF expression induced by rAd-HGF infection with the higher MOIs. Such pro-proliferative effects became more remarkable at the later timepoints of the observation period ( Figure 2C,D) . Consistent with the secretion of HGF, the highest level of cell proliferation was observed in cells infected with rAd-HGF at MOI = 250 ( Figure  2C ). 
hBMSC Osteogenic Differentiation Induced by Serial MOIs of rAd-HGF Infection
To study the MOI influence of rAd-HGF infection on hBMSC differentiation, the osteogenesis was induced by changing the growth medium to differentiation medium and then hBMSCs were infected by serial MOIs of rAd-HGF. Two weeks later, the degree of osteogenic differentiation indicated by calcium accumulation was evaluated using AR-S staining. Most hBMSCs infected with 
To study the MOI influence of rAd-HGF infection on hBMSC differentiation, the osteogenesis was induced by changing the growth medium to differentiation medium and then hBMSCs were infected by serial MOIs of rAd-HGF. Two weeks later, the degree of osteogenic differentiation indicated by calcium accumulation was evaluated using AR-S staining. Most hBMSCs infected with a relatively high-level of rAd-Ctrl spread relatively evenly in the culture surface, accompanied with the relatively even AR-S staining. In contrast, rAd-HGF-infected cells with AR-S positive staining were clustered together to form calcium nodules that distributed unevenly. In the central of the calcium nodules formed by hBMSCs infected with rAd-HGF but not rAd-Ctrl, AR-S staining showed deep to dark color which indicated higher expression of osteocalcin. The results showed that osteogenic differentiation of hBMSCs gradually enhanced along with the ascending MOIs of rAd-HGF as indicated by the remarkable increase in the formation of mineralized extracellular matrix (ECM). Cells infected with rAd-HGF at MOI = 10 or 50 showed no apparent difference of mineralized ECM formation compared with rAd-Ctrl-infected cells. However, when MOI elevated to 250 or 1250, we observed significantly enhanced osteogenic differentiation in hBMSCs infected with rAd-HGF than in those infected with rAd-Ctrl ( Figure 3 ). 
Roles of Different Signaling Pathways in hBMSC Proliferation Induced by rAd-HGF Infection
Our previous studies have shown that ERK1/2 and PI3K/AKT signaling pathways are involved in regulating the proliferation and osteogenesis of BMSCs [12] . The WNT signaling pathway was reported to regulate the transcription of many genes, among them, the induction of RUNX2 promotes BMSC osteogenic differentiation [18] . To explore the roles of signaling pathways on the hBMSC proliferation and osteogenic differentiation induced by rAd-HGF infection, corresponding inhibitors against the above pathways were used. As various MOIs of rAd-HGF induced significantly different effects on proliferation and osteogenic differentiation in hBMSCs, with the highest levels were observed at MOI = 250, and in the osteogenic differentiation medium, the level of secreted HGF by hBMSCs infected with rAd-HGF was significantly higher than that by cells infected with rAd-Ctrl only at MOI = 250, but not at MOI = 50, as indicated by the results of ELISA (Figure 4A ), the impacts of signaling pathways on proliferation and osteogenesis of hBMSCs were evaluated with rAd-HGF infection at this MOI. The inhibitory effects on these signaling pathways have been confirmed using Western blot analysis ( Figure S1 ). The impact of recombinant adenovirus infection combined with inhibitor treatment on cell status was observed under the microscope ( Figure S2) , and results of WST-8 assays indicated that, in osteogenic differentiation medium, treatment with different inhibitors resulted in various effects on cell proliferation. In contrast to that in the growth medium, rAd-HGF 
Our previous studies have shown that ERK1/2 and PI3K/AKT signaling pathways are involved in regulating the proliferation and osteogenesis of BMSCs [12] . The WNT signaling pathway was reported to regulate the transcription of many genes, among them, the induction of RUNX2 promotes BMSC osteogenic differentiation [18] . To explore the roles of signaling pathways on the hBMSC proliferation and osteogenic differentiation induced by rAd-HGF infection, corresponding inhibitors against the above pathways were used. As various MOIs of rAd-HGF induced significantly different effects on proliferation and osteogenic differentiation in hBMSCs, with the highest levels were observed at MOI = 250, and in the osteogenic differentiation medium, the level of secreted HGF by hBMSCs infected with rAd-HGF was significantly higher than that by cells infected with rAd-Ctrl only at MOI = 250, but not at MOI = 50, as indicated by the results of ELISA (Figure 4A ), the impacts of signaling pathways on proliferation and osteogenesis of hBMSCs were evaluated with rAd-HGF infection at this MOI. The inhibitory effects on these signaling pathways have been confirmed using Western blot analysis ( Figure S1 ). The impact of recombinant adenovirus infection combined with inhibitor treatment on cell status was observed under the microscope ( Figure S2) , and results of WST-8 assays indicated that, in osteogenic differentiation medium, treatment with different inhibitors resulted in various effects on cell proliferation. In contrast to that in the growth medium, rAd-HGF infections led to a significant decrease in the total number of cells in osteogenic differentiation medium with mock treatments of DMSO as controls (Figure 4B-E) .
induced hBMSC proliferation in the osteogenic medium ( Figure 4C Figure 4D ).
Contrary to the ERK1/2 pathway, the PI3K/AKT pathway has been reported to promote rat BMSC osteogenic differentiation [20] . In this study, the role of the PI3K/AKT pathway in proliferation was also detected. As expected, no obvious effect on cell proliferation was observed with LY294002 treatment, suggesting that the PI3K/AKT pathway did not take part in the regulation of hBMSC proliferation in the osteogenic differentiation medium ( Figure 4E ). Roles of signaling pathways in HGF secretion and cell proliferation of hBMSCs infected with recombinant adenoviruses. Human BMSCs were cultured in the osteogenic differentiation medium and treated with various signal pathway inhibitors or DMSO before infection. Three days later, HGF secretion by cells treated with DMSO were evaluated using ELISA (A), and cell proliferation was detected using the WST-8 method (B-E). * p < 0.05, ** p < 0.01, *** p < 0.001. The experiment has been replicated three times with similar results, and the representative results were shown.
However, using SU11274 to inhibit the HGF receptor, c-MET, significantly suppressed the cell proliferation, no matter whether cells were infected with rAd-HGF or with rAd-Ctrl. Unexpectedly, cells infected with rAd-HGF could not counteract the anti-proliferative effects to c-MET signaling by inhibitor SU11274. In comparison, SU11274 treatment further inhibited the proliferation of cells infected with rAd-HGF, resulting in the lowest level of proliferation in hBMSCs infected with rAd-HGF but not in cells with rAd-Ctrl. This result suggests that HGF-induced cell proliferation is dependent on c-MET activity ( Figure 4B) .
Meanwhile, roles of other c-MET downstream signaling pathways were detected. For this goal, the WNT inhibitor, Wnt-C59, was used to treat cells before rAd-HGF infection. Unexpectedly, when cells were infected with recombinant adenoviruses, inhibiting the WNT pathway significantly suppressed cell proliferation induced by rAd-HGF infection when compared with the rAd-Ctrl-infected 7 of 12 cells treated with DMSO (p < 0.05). However, for cells infected with rAd-HGF, there was no significant difference between the proliferation level of cells treated with DMSO and that of cells treated with Wnt-C59. Meanwhile, for cells treated with Wnt-C59, there is no significant difference in proliferation observed between cells infected with rAd-HGF and cells infected with rAd-Ctrl. These results indicated that the WNT pathway did not play important roles in the rAd-HGF infection-induced hBMSC proliferation in the osteogenic medium ( Figure 4C) .
Another signaling pathway involved in cell proliferation was the ERK1/2 pathway. Pre-treatment of cells with the corresponding inhibitor U0126 significantly inhibited cell proliferation when compared with DMSO-treated and rAd-Ctrl-infected cells. Meanwhile, U0126 treatment resulted in significant decrease in the proliferation level of cells infected with rAd-HGF compared with rAd-HGF-infected cells treated with DMSO (p < 0.05), indicating that HGF induced cell proliferation by activating ERK1/2 signaling pathway downstream of c-MET ( Figure 4D ).
Contrary to the ERK1/2 pathway, the PI3K/AKT pathway has been reported to promote rat BMSC osteogenic differentiation [20] . In this study, the role of the PI3K/AKT pathway in proliferation was also detected. As expected, no obvious effect on cell proliferation was observed with LY294002 treatment, suggesting that the PI3K/AKT pathway did not take part in the regulation of hBMSC proliferation in the osteogenic differentiation medium ( Figure 4E ).
Roles of Different Signaling Pathways in hBMSC Osteogenic Differentiation Induced by rAd-HGF Infection
Subsequently, the roles of above signaling pathways in hBMSC osteogenic differentiation were examined by treatments with the corresponding inhibitors. The degree of osteogenic differentiation was also assessed by the concentration of AR-S stained in the calcium nodules that formed by the hBMSCs. The results in DMSO-treated cells clearly indicated that the pro-osteogenic effects induced by rAd-HGF infection were significantly enhanced compared with that of rAd-Ctrl-infected cells (p < 0.01) (Figure 5A-D secretion by cells treated with DMSO were evaluated using ELISA (A), and cell proliferation was detected using the WST-8 method (B-E). *, p < 0.05, **, p < 0.01, *** p < 0.001. The experiment has been replicated three times with similar results, and the representative results were shown.
Subsequently, the roles of above signaling pathways in hBMSC osteogenic differentiation were examined by treatments with the corresponding inhibitors. The degree of osteogenic differentiation was also assessed by the concentration of AR-S stained in the calcium nodules that formed by the hBMSCs. The results in DMSO-treated cells clearly indicated that the pro-osteogenic effects induced by rAd-HGF infection were significantly enhanced compared with that of rAd-Ctrl-infected cells (p < 0.01) (Figure 5A-D) .
Interestingly, treatment with SU11274 promoted osteogenic differentiation of cells infected with rAd-Ctrl when compared with DMSO-treated and rAd-Ctrl-infected cells (p < 0.05). Such promotion resulting from inhibition of c-MET could not be observed again when cells were infected with rAd-HGF. However, inhibition of c-MET led to the loss of pro-osteogenic effects in hBMSCs with rAd-HGF infection compared with DMSO-treated and rAd-HGF-infected cells. Together, the above results indicated that HGF-induced c-MET activation contributes to hBMSC osteogenic differentiation ( Figure 5A ).
Considering the ineffectiveness of the WNT signaling pathway on hBMSC proliferation observed above, its function on the osteogenic differentiation is worth determining. Strikingly, in both DMSO-treatment and Wnt-C59 treatment groups, rAd-HGF infection significantly promoted osteogenic differentiation compared with rAd-Ctrl infection (p < 0.001), which demonstrated the antiosteogenic role of the WNT signaling pathway in hBMSCs. Further, the osteogenic degree of the Wnt-59-treatment group was significantly enhanced compared with the DMSO-treatment group ( Figure  5B ). This finding suggested that the WNT signaling pathway is a critical anti-osteogenic regulator for the osteogenic differentiation of hBMSCs induced by HGF, and inhibition of the WNT pathway by Wnt-C59 may be a promising way to promote hBMSC osteogenesis ( Figure 5B) .
Meanwhile, consistent with the well-known function of the ERK1/2 pathway in promoting cell proliferation, our data indicated that inhibition of the ERK1/2 signaling has no significant effects on hBMSC osteogenic differentiation ( Figure 5C ). Interestingly, treatment with SU11274 promoted osteogenic differentiation of cells infected with rAd-Ctrl when compared with DMSO-treated and rAd-Ctrl-infected cells (p < 0.05). Such promotion resulting from inhibition of c-MET could not be observed again when cells were infected with rAd-HGF. However, inhibition of c-MET led to the loss of pro-osteogenic effects in hBMSCs with rAd-HGF infection compared with DMSO-treated and rAd-HGF-infected cells. Together, the above results indicated that HGF-induced c-MET activation contributes to hBMSC osteogenic differentiation ( Figure 5A ).
Considering the ineffectiveness of the WNT signaling pathway on hBMSC proliferation observed above, its function on the osteogenic differentiation is worth determining. Strikingly, in both DMSO-treatment and Wnt-C59 treatment groups, rAd-HGF infection significantly promoted osteogenic differentiation compared with rAd-Ctrl infection (p < 0.001), which demonstrated the anti-osteogenic role of the WNT signaling pathway in hBMSCs. Further, the osteogenic degree of the Wnt-59-treatment group was significantly enhanced compared with the DMSO-treatment group ( Figure 5B ). This finding suggested that the WNT signaling pathway is a critical anti-osteogenic regulator for the osteogenic differentiation of hBMSCs induced by HGF, and inhibition of the WNT pathway by Wnt-C59 may be a promising way to promote hBMSC osteogenesis ( Figure 5B) .
Meanwhile, consistent with the well-known function of the ERK1/2 pathway in promoting cell proliferation, our data indicated that inhibition of the ERK1/2 signaling has no significant effects on hBMSC osteogenic differentiation ( Figure 5C ).
Interestingly, inhibition of the PI3K/AKT pathway in rAd-Ctrl-infected cells by LY294002 did not suppress the osteogenic differentiation compared with the same cells treated with DMSO. However, in the case of LY294002 treatment, more significant suppression in osteogenic differentiation was observed in cells with rAd-HGF infection (p < 0.05), which is as an even more obvious situation when compared with DMSO-treated hBMSCs infected with rAd-HGF (p < 0.001). This finding suggested the important pro-osteogenic roles of PI3K/AKT pathway in rAd-HGF-induced hBMSC osteogenic differentiation ( Figure 5D ).
Discussion
BMSC adoptive cell therapy is a promising approach for ANFH. As a self-secreted cytokine, pleiotropic HGF has been demonstrated to play important roles in BMSC activity. In this study, the MOI-dependent effects of rAd-HGF infection for HGF expression on hBMSC proliferation and osteogenic differentiation have been explored, while the roles of c-MET-related signaling pathways are also investigated. Our results indicated that higher MOIs of rAd-HGF (MOI = 250 or MOI = 1250) not only significantly promoted HGF expression, but also played stronger roles to enhance hBMSC proliferation and osteogenic differentiation than rAd-Ctrl and low MOIs of rAd-HGF (MOI = 10 or MOI = 50) did. As MOI 250 showed the strongest effects in producing HGF and promoting both proliferation and osteogenesis of hBMSCs, it was selected for further evaluating the influences of HGF receptor c-MET-related signaling pathways in hBMSC proliferation and osteogenesis. Interestingly, inhibitor-treatment experiments showed that the WNT pathway plays anti-osteogenic roles while the PI3K/AKT pathway is pro-osteogenic for hBMSCs.
Signaling pathways play complex roles in cell bioactivity, also in that of hBMSCs in osteogenic differentiation environment as we demonstrated in this study. As the receptor of HGF on BMSCs, c-MET suppressed by SU11274 treatment significantly inhibited the proliferation of cells infected with both recombinant adenoviruses compared with DMSO-treated cells, and that of cells infected with rAd-HGF compared with cells infected with rAd-Ctrl, indicating that HGF promotes hBMSC proliferation through activating c-MET signaling. In addition, as expected, the ERK1/2 pathway activated by HGF functioned as a remarkable enhancing factor to promote hBMSC proliferation in the osteogenic differentiation condition. On the contrary, WNT signaling has been reported to regulate transcription of multiple genes, including the RUNX2 which promotes BMSC osteogenic differentiation [18] . For this reason, in this study, the WNT pathway was supposed to enhance BMSC osteogenic differentiation and possibly inhibit BMSC proliferation. However, when treated with Wnt-C59 to inhibit the WNT signaling, no effects on cell proliferation were observed when compared the DMSO-treated cells and the inhibitor-treated cells infected with the same recombinant adenovirus. The only difference appeared between Wnt-C59-treated and rAd-HGF-infected cells and DMSO-treated and rAd-Ctrl-infected cells (p < 0.05). These results indicated that the WNT pathway exerted no effects in hBMSC proliferation in the osteogenic medium. Similarly, the PI3K/AKT pathway also showed few effects on cell proliferation. These observations revealed that the c-MET and the ERK1/2 signaling pathways are involved in promotion of hBMSC proliferation in the osteogenic differentiation medium. However, rAd-HGF infection could inhibit these two pathways to suppress hBMSC proliferation under this condition.
It is well known that cell proliferation and differentiation are two opposite biological activities and regulated by different but maybe interactive signaling pathways. In this study, our results indicated that c-MET mainly promoted proliferation of hBMSCs. However, at the same time, inhibiting c-MET eliminated the promotive effects of rAd-HGF infection on hBMSC osteogenesis, indicating that c-MET also contributed to hBMSC differentiation. However, when cells were infected with rAd-Ctrl, treatment with SU11274 could greatly promote cell osteogenesis. Because BMSCs could self-secret HGF, this result suggested that the regulatory effects of c-MET were obvious at low dose of HGF, thus inhibiting c-MET not only inhibited cell proliferation, but also enhanced hBMSC osteogenic differentiation induced by self-secreted HGF. Meanwhile, consistent with the activity to promote cell proliferation, the ERK1/2 pathway exerted few effects on osteogenesis. These results indicated that the two cellular activities, proliferation and differentiation, indeed are opposite to each other. Interestingly, inhibition of the WNT pathway significantly promoted cell osteogenesis, contrary to the previous report on its promotive role in osteogenesis [18] . When rAd-HGF-infected hBMSCs were treated with Wnt-C59, the osteogenic degree was significantly higher than rAd-Ctrl-infected cells treated with DMSO (p < 0.001). Meanwhile, rAd-HGF-infected cells treated with DMSO showed comparable osteogenic degree when compared with rAd-Ctrl-infected cells treated with Wnt-C59, which suggested the HGF may be an inhibitory factor of the WNT pathway to promote hBMSC osteogenesis. In the meantime, as expected, our results indicated that the PI3K/AKT pathway indeed promoted hBMSC osteogenic differentiation. Treatment with LY294002 could greatly suppress the level of hBMSC osteogenesis elevated by rAd-HGF infection. Furthermore, similar osteogenic degrees between rAd-Ctrl-infected cells treated with DMSO and rAd-HGF-infected cells treated with LY294002 indicated that LY294002 could counteract the pro-osteogenic effects of the PI3K/AKT pathway after HGF activation. In summary, in rAd-HGF-infected hBMSCs, HGF induced activation of the PI3K/AKT pathway and inhibition of the WNT pathway functioned together to promote cell osteogenesis.
Here, we demonstrated the MOI-dependent effects of rAd-HGF on HGF expression and the proliferation and osteogenesis of hBMSCs, as well as the roles of various signaling pathways in rAd-HGF-mediated hBMSC proliferation and osteogenesis. Besides the positive regulatory roles of rAd-HGF with MOI = 250 in osteogenesis of hBMSCs, results of pathway-specific inhibitor treatments also demonstrated that the WNT pathway plays anti-osteogenic roles while the PI3K/AKT pathway is pro-osteogenic for hBMSCs. Our finding suggest that combinatory application of high MOI rAd-HGF (MOI = 250) with inhibitor of WNT pathway, like Wnt-C59, is a promising modality for the better application of HGF gene-modified hBMSCs in ANFH therapy.
Materials and Methods
Cell Cultures
Human bone marrow mesenchymal stem cells (hBMSCs) were bought from Cyagen Biosciences Inc., (Goleta, CA, USA). Informed consent was obtained in accordance with the Declaration of Helsinki and the Institutional Review Board of the Southern Medical University (approval number SMU-2015123, 2016.01.10). Cells were cultured at 37 • C, 5% CO 2 , in the Human Mesenchymal using FluorChem Q Multi-Functional Imaging and Analysis System (ProteinSimple Ltd., San Jose, CA, USA).
Statistical Analysis
Data are expressed as the mean ± SD. The statistical significance was determined using one-way ANOVA. Post hoc multiple comparisons were performed using least significant difference or Dunnett's T3. Differences with p < 0.05 were statistically significant. All statistical analyses were performed with SPSS statistical software version 16.0 (SPSS, Chicago, IL, USA).
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/3/734/s1.
